Surface treatment for a medical device

• US 9,023,314 B2
• Filed: 09/30/2009
• Issued: 05/05/2015
• Est. Priority Date: 09/30/2008
• Status: Active Grant

• Current Assignee: Covidien LP (Medtronic Plc)
• Original Assignee: Covidien LP (Medtronic Plc)
• Inventors: O'Neil, Michael P.
• Primary Examiner(s): Hartley, Michael G
• Assistant Examiner(s): LAMBERSKI, JENNIFER A
• Application Number:
  US12/570,508
• Publication Number:
  US 20100139663A1
• Time in Patent Office: 2,043 Days
• Field of Search: None
• US Class Current: 424/1.29
• CPC Class Codes: A61M 16/04 Tracheal tubes catheters in general A61M25/00
• CPC Class Codes: A61M 2205/0233 Conductive materials, e.g. antistatic coatings for spark prevention
• CPC Class Codes: C08J 7/12 Chemical modification

Abstract

A surface coating for a medical device is provided that may prevent or slow the formation of medical biofilms on the surface of the device. Covalent attachment of certain analogues of N-acyl L-homoserine lactones onto a medical device may provide the advantage of slowing biofilm formation in a manner that is targeted to the surface of the medical device and not the patient. Such a device may allow healthcare providers to prevent bacterial buildups on the surfaces of the device, which may lead to biofilm formation.

Claims

1. An airway device comprising:

a conduit for insertion into a patient'"'"'s trachea; and

an acyl-homoserine lactone analog comprising a hydrocarbon tether covalently bound directly to a surface of the conduit, wherein the acyl-homoserine lactone analog is a non-microbicidal compound configured to interrupt bacterial communication to reduce biofilm formation on the conduit when the conduit is inserted into the trachea, and wherein the conduit which is covalently bound to the acyl-homoserine lactone analog comprising a hydrocarbon tether has a Formula (II),

2. The airway device recited in claim 1, wherein the airway device comprises an endotracheal tube or a tracheotomy tube.

3. The airway device recited in claim 1, wherein n is greater than m.

4. The airway device recited in claim 1, wherein n is 4 and m is 1.

5. A method of manufacturing an airway device comprising:

activating a surface of the airway device via plasma treatment, wherein the airway device comprises a conduit for insertion into a patient'"'"'s trachea;

covalently binding at least one hydrocarbon spacer molecule to the activated surface of the conduit; and

covalently binding a non-microbicidal acyl-homoserine lactone analog to the at least one hydrocarbon spacer molecule bound to a surface of the conduit, wherein the conduit which is covalently bound to the acyl-homoserine lactone analog via the at least one hydrocarbon tether has a Formula (II),

6. The method of claim 5, comprising covalently binding a second hydrocarbon spacer molecule to the activated surface of the airway device before covalently binding the non-microbicidal acyl-homoserine lactone analog.

7. The method of claim 5, wherein n is greater than m.

8. The method of claim 7, wherein n is 4 and m is 1.

9. An airway device system comprising:

a conduit for insertion into a patient'"'"'s trachea; and

an acyl-homoserine lactone analog having a hydrocarbon tether covalently bound directly to the conduit, wherein the acyl-homoserine lactone analog is configured to reduce biofilm formation on the conduit when the conduit is inserted into the trachea without killing one or more microorganisms associated with the biofilm formation, wherein the conduit which is covalently bound to the acyl-homoserine lactone analog having a hydrocarbon tether has a Formula (II),

10. The system recited in claim 9, wherein n is greater than m.

11. The system recited in claim 9, wherein n is 4 and m is 1.

12. An airway device, comprising:

a polymeric device body having one or more surfaces comprising a plurality of attachment sites, wherein at least one surface comprises one or more non-microbicidal acyl-homoserine lactone analogs that are directly, covalently attached to a portion of the attachment sites via hydrocarbon tethers, wherein the one or more acyl-homoserine lactone analogs are configured to prevent biofilm formation by interrupting bacterial communication, and wherein the polymeric device body which is covalently attached to the one or more acyl- homoserine lactone analogs via the hydrocarbon tethers has a Formula (II),

13. The airway device recited in claim 12, wherein the one or more non-microbicidal acyl-homoserine lactone analogs are directly, covalently attached to 1 in 4 of the attachment sites of the one or more surfaces of the polymeric device.

14. The airway device recited in claim 12, wherein n is greater than m.

15. The airway device recited in claim 12, wherein n is 4 and m is 1.